Mutual of America Capital Management LLC Sells 492 Shares of Masimo Corporation $MASI

Mutual of America Capital Management LLC lessened its stake in shares of Masimo Corporation (NASDAQ:MASI) by 2.2% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,379 shares of the medical equipment provider’s stock after selling 492 shares during the period. Mutual of America Capital Management LLC’s holdings in Masimo were worth $3,765,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Masimo by 0.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock valued at $1,894,000 after purchasing an additional 66 shares during the last quarter. Xponance Inc. boosted its stake in Masimo by 1.1% during the 1st quarter. Xponance Inc. now owns 7,101 shares of the medical equipment provider’s stock valued at $1,183,000 after purchasing an additional 76 shares during the last quarter. Deutsche Bank AG boosted its stake in Masimo by 1.5% during the 1st quarter. Deutsche Bank AG now owns 6,309 shares of the medical equipment provider’s stock valued at $1,051,000 after purchasing an additional 92 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in Masimo by 0.8% during the 1st quarter. Louisiana State Employees Retirement System now owns 12,400 shares of the medical equipment provider’s stock valued at $2,066,000 after purchasing an additional 100 shares during the last quarter. Finally, Securian Asset Management Inc. boosted its stake in Masimo by 3.0% during the 1st quarter. Securian Asset Management Inc. now owns 3,433 shares of the medical equipment provider’s stock valued at $572,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.

Analyst Upgrades and Downgrades

MASI has been the topic of several recent analyst reports. BTIG Research reiterated a “buy” rating and set a $198.00 target price on shares of Masimo in a research note on Thursday, September 11th. Zacks Research upgraded Masimo from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 3rd. Weiss Ratings reiterated a “sell (d)” rating on shares of Masimo in a research note on Wednesday, October 8th. Piper Sandler increased their target price on Masimo from $200.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 6th. Finally, Wall Street Zen upgraded Masimo from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Masimo currently has a consensus rating of “Moderate Buy” and an average target price of $194.60.

Masimo Stock Performance

MASI stock opened at $148.73 on Friday. The company has a market cap of $8.08 billion, a P/E ratio of -17.46 and a beta of 1.28. Masimo Corporation has a 1 year low of $133.70 and a 1 year high of $194.88. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.14 and a quick ratio of 1.61. The stock’s fifty day moving average price is $145.32 and its 200-day moving average price is $154.48.

Masimo (NASDAQ:MASI) last released its earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share for the quarter. The company had revenue of $617.00 million for the quarter. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%. On average, equities analysts forecast that Masimo Corporation will post 4.1 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director William R. Jellison bought 3,000 shares of the stock in a transaction that occurred on Monday, August 11th. The shares were bought at an average cost of $145.98 per share, for a total transaction of $437,940.00. Following the completion of the transaction, the director owned 4,790 shares of the company’s stock, valued at approximately $699,244.20. This trade represents a 167.60% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 9.70% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.